NAMS
The table below shows NewAmsterdam Pharma Company N.V.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $3.04M | $348.00K | $19.14M | $2.98M | $29.11M | $2.28M |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $38.01M | $30.97M | $27.52M | $44.75M | $35.70M | $38.38M |
NewAmsterdam Pharma Company N.V. reported annual revenue of $22.50M for fiscal year 2025. That is down 50.6% from $45.56M in fiscal 2024. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $23.45M |
| $24.52M |
| $27.26M |
| $27.15M |
| $18.41M |
| $16.48M |
| Operating income | -$58.42M | -$55.14M | -$35.63M | -$68.92M | -$25.00M | -$52.58M |
| Income tax | - | - | - | - | -$1.00K | - |
| Net income | -$48.44M | -$72.00M | -$17.36M | -$39.53M | -$16.65M | -$39.01M |
| EPS (diluted) | -$0.40 | -$0.61 | -$0.15 | -$0.34 | -$0.18 | -$0.41 |